Home  |  Contact

Cellosaurus EB66 (CVCL_G703)

[Text version]

Cell line name EB66
Accession CVCL_G703
Resource Identification Initiative To cite this cell line use: EB66 (RRID:CVCL_G703)
Comments Group: Bird cell line.
Group: Serum/protein free medium cell line.
Group: Vaccine production cell line.
From: Valneva SE; France.
Species of origin Anas platyrhynchos (Mallard) (Anas boschas) (NCBI Taxonomy: 8839)
Breed/subspecies: GL30.
Sex of cell Male
Age at sampling Blastocyst stage
Category Embryonic stem cell
Web pages http://www.valneva.com/en/technologies/82
Publications

PubMed=20562528
Olivier S., Jacoby M., Brillon C., Bouletreau S., Mollet T., Nerriere O., Angel A., Danet S., Souttou B., Guehenneux F., Gauthier L., Berthome M., Vie H., Beltraminelli N., Mehtali M.
EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activity.
MAbs 2:405-415(2010)

PubMed=21502045
Brown S.W., Mehtali M.
The avian EB66(R) cell line, application to vaccines, and therapeutic protein production.
PDA J. Pharm. Sci. Technol. 64:419-425(2010)

PubMed=25903999; DOI=10.1002/biot.201400388
Genzel Y.
Designing cell lines for viral vaccine production: where do we stand?
Biotechnol. J. 10:728-740(2015)

PubMed=26409141; DOI=10.1016/j.vaccine.2015.09.022
Naruse T., Fukuda T., Tanabe T., Ichikawa M., Oda Y., Tochihara S., Kimachi K., Kino Y., Ueda K.
A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03.
Vaccine 33:6078-6084(2015)

Patent=US9260694
Guehenneux F., Moreau K., Esnault M., Mehtali M.
Generation of duck cell lines.
Patent number US9260694, 16-Feb-2016

Cross-references
Other Wikidata; Q54831755
Entry history
Entry creation11-Feb-2013
Last entry update07-Sep-2018
Version number12